The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

Patients who would benefit most from surgery and are least likely to benefit from continued medical therapy alone should be identified ...

It's not likely that shoppers will come across any fresh tomatoes from the recalled batch, according to the FDA.

Clinically relevant but not statistically significant improvement seen in anxiety and fatigue versus usual services.

Most pushback due to child expectations of vaccine-free visit at 9 years; discussions shorter since sexual activity not perceived as salient.

A phase 1 trial, LUMINA, is currently underway and is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMX0114 in approximately 48 patients with ALS.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes ...

The discovery evidence in this case, particularly the deposition evidence, made it clear that the plaintiff had a strong case against the hospital.

Xenoview is a hyperpolarized xenon inhaled contrast agent indicated for use with magnetic resonance imaging for evaluation of lung ventilation.

Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

The ASCENT-03 trial is a phase 3 study assessing the efficacy and safety of sacituzumab govitecan compared with physician’s choice of treatment in patients with previously untreated, locally advanced, ...